On Jan 29 in London, French pharmaceutical company Sanofi outlined expectations for its revenue trajectory into 2026 and disclosed a new share repurchase plan.
Sanofi said it anticipates sales to grow by a high-single-digit percentage in 2026, citing robust demand for Dupixent - its leading asthma treatment developed with partner Regeneron - along with contributions from several more recently introduced medicines. The company additionally expects business operating income to expand slightly faster than sales in the current year.
As part of its capital allocation moves, Sanofi announced a plan to repurchase 1 billion euros of its own shares. This follows the firm completing a 5 billion euro buyback programme during 2025.
Management has been pursuing new sources of revenue to prepare for the eventual loss of exclusivity for Dupixent in 2031, and has signalled a more active stance on mergers and acquisitions.
Among the transactions closed in 2025, Sanofi completed a purchase of Blueprint Medicines for $9.5 billion, acquiring an approved therapy for a rare blood disorder. The company also agreed in December to acquire adult vaccine maker Dynavax Technologies for $2.2 billion, and in July finalised a $1.5 billion acquisition of British private vaccine developer Vicebio.
For the fourth quarter, Sanofi reported business operating income of 2.34 billion euros. That figure compared with an average analyst expectation of 2.37 billion euros in a company-provided poll.
Quarterly sales for Dupixent reached 4.25 billion euros, exceeding the average analyst forecast of 4.05 billion euros.
The company provided a currency conversion note in its report, stating that $1 = 0.8345 euros.
Summary
Sanofi expects 2026 sales growth in the high single digits, with business operating income projected to grow slightly faster than sales this year. The company will repurchase 1 billion euros of shares after completing a 5 billion euro programme in 2025, and has pursued acquisitions including Blueprint Medicines, Dynavax Technologies, and Vicebio. Dupixent continues to drive strong quarterly sales.